INCR -- Incara Pharmaceuticals | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
INCR -- Incara Pharmaceuticals

An SI Board Since September 2000

Posts	SubjectMarks	Bans	Symbol
196	10	0	INCR

Emcee: scaram(o)uche	Type: Unmoderated

Introduction Market Data Compact

Currently up about 20% on today's news. Not a proponent of the company, I'm interested in learning more about their catalytic antioxidants. Note also that they've been making news for a STEM-like project with liver stem cells......

Wednesday September 6, 9:13 am Eastern Time

Press Release

SOURCE: Incara Pharmaceuticals Corporation

Incara Announces Patent on Small-Molecule
Antioxidants; Catalytic Antioxidants Active in Preclinical Models of
Stroke, Reperfusion Injury

RESEARCH TRIANGLE PARK, N.C., Sept. 6 /PRNewswire/ --

Incara Pharmaceuticals Corporation (Nasdaq: INCR - news) today announced issuance of the U.S. patent for
``Oxidoreductase Activity of Manganic Porphyrins.'' Incara licenses the patent from Duke University as part of a research
collaboration in the field of antioxidants. The oxidoreductase activity described in the patent represents a novel mechanism of
action for certain small molecules acting as catalytic antioxidants and is an extension of Incara's ongoing small molecule
antioxidant research and development program.

Incara's small molecule antioxidants catalytically degrade the free radicals superoxide and peroxynitrite. Free radicals cause cell
damage by reacting with proteins, lipids and DNA. Scientists believe that damage caused by free radicals plays a role in many
diseases, including stroke and inflammatory diseases.

In preclinical models of stroke, Incara's lead catalytic antioxidant molecule, AEOL 10113, has consistently demonstrated
dramatic reduction in infarct size. Significant reduction of infarct volume was found even when the compound was administered
as late as 7.5 hours after the onset of ischemia. AEOL 10113 has also been shown to exert a protective effect in preclinical
models of liver and cardiac ischemia and reperfusion injury.

Incara's catalytic antioxidant program was founded by Irwin Fridovich, Ph.D. of Duke University School of Medicine, the
co-discoverer of the endogenous antioxidant enzyme superoxide dismutase, and James D. Crapo, M.D. of National Jewish
Medical and Research Center, a pulmonologist and antioxidant researcher.

``Our latest catalytic antioxidants are more active than the natural SOD enzyme on a weight basis,'' said Dr. Fridovich. ``Their
ability to penetrate cells and tissues could make them effective antioxidants for therapeutic applications.''

``We believe that our catalytic antioxidants have great potential in the treatment of human disease,'' said Clayton I. Duncan,
Chairman and CEO of Incara Pharmaceuticals. ``We plan to start clinical trials in stroke next year.''

Incara Pharmaceuticals Corporation (http://www.incara.com ) is developing a diversified portfolio of proprietary therapies
oriented to major advances in treatment of diseases afflicting large patient populations. The Company's three current programs
include liver precursor cell therapy for the treatment of liver failure, an ultra-low molecular weight heparin for the treatment of
inflammatory bowel disease and catalytic antioxidants for treatment of stroke, reperfusion injury and chronic bronchitis.

The statements in this press release that are not purely statements of historical fact are forward-looking statements, and actual
results may differ materially from those anticipated. These statements and other statements made elsewhere by the Company or
its representatives, which are identified or qualified by words such as ``likely,'' ``will,'' ``suggests,'' ``expects,'' ``might,'' ``may,''
``believe,'' ``could,'' ``should,'' ``would,'' ``anticipates,'' ``plans'' or similar expressions, are based on a number of assumptions
that are subject to risks and uncertainties. Important factors that could cause results to differ include uncertainties of scientific
research, risks associated with the need to obtain funds for operations, clinical trials and product development activities. These
and other important risks are described in Incara's reports on Form S-1, Form 10-K, Form 10-Q and Form 8-K filed with the
Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. The Company assumes no obligation to update the information in this release.

SOURCE: Incara Pharmaceuticals Corporation

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
196	<<"My skills at fundraising ... really weren't needed">&g	rkrw	-	12/29/2006
195	<i>Ercole? Oh yeah, I'm going to get in line to invest in a Duncan co	scaram(o)uche	-	12/29/2006
194	Just for the record (you never know what the future may hold department) INCR un	tom pope	-	10/9/2004
193	biz.yahoo.com Press Release Source: Incara Pharmaceuticals Corporation Incara	hmpa	-	4/19/2004
192	For those who still have INCR in their portfolios(?) (I still do, but won't	tom pope	-	12/17/2003
191	>>One hell of a five day chart. Is the patent that much of a big deal?>	Icebrg	-	5/6/2003
190	One hell of a five day chart. Is the patent that much of a big deal? finance.y	Micawber	-	5/6/2003
189	From the Proxy: <i>The Board believes that the increase number of authori	Micawber	-	2/19/2003
188	Incara Closes Liver Cell Program Divestiture Updated: Friday, November 1, 200	mopgcw	-	11/1/2002
187	1. I can't profit much from trading stocks down in the dime range. 2. The	scaram(o)uche	-	10/22/2002
186	Not long ago they said liver was their best program.	keokalani'nui	-	10/22/2002
185	Worth another look now that they're focused on their best program? >>	tuck	-	10/22/2002
184	Incara Stock Moves to OTC Bulletin Board Market PR Newswire, Wednesday, Sep	mopgcw	-	9/25/2002
183	>>Bennett also noted that potential investors who have looked at the busin	tuck	-	9/20/2002
182	Anyone think INCR is worth gamble at .10? Finances sure look bad. Sep 20, 20	Findit	-	9/20/2002
181	Reported: August 14 Incara Pharmaceuticals Corp. (INCR) Incara Pharmaceuticals	mopgcw	-	8/19/2002
180	Study Published in Journal Diabetes Shows Incara's Catalytic Antioxidant Inc	mopgcw	-	8/15/2002
179	Incara Announces Results for Third Quarter of Fiscal 2002 RESEARCH TRIANGLE PAR	mopgcw	-	8/13/2002
178	Incara IND for Liver Cell Transplantation Allowed by FDA RESEARCH TRIANGLE PARK	mopgcw	-	7/30/2002
177	I wouldn't be at all surprised. I think that it's a great second projec	scaram(o)uche	-	7/26/2002
176	messages.yahoo.com For What It's Worth by: keith_dmg Long-Term Sentiment:	mopgcw	-	7/25/2002
175	Bottom falling out of INCR bid/ask at .19/.20. No news, just swooning with the m	Findit	-	7/10/2002
174	<i>sloppy crap from Incara</i> Market isn't impressed, in fact	tom pope	-	6/28/2002
173	<i>One donor liver may provide sufficient numbers of liver cells for multi	scaram(o)uche	-	6/28/2002
172	Incara Submits IND for Liver Cell Transplantation RESEARCH TRIANGLE PARK, N.C.,	mopgcw	-	6/28/2002

Go to reply# or date (mm/dd/yy):